Stockreport

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis [Yahoo! Finance]

Rein Therapeutics, Inc.  (RNTX) 
PDF AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class me [Read more]